Clinical Trial Update: A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating prophylactic emicizumab versus no prophylaxis in Hemophilia A patients without inhibitors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2018-11-14